Bristol-Myers Receives FDA Approval for Injectable Opdivo (BMY:NYSE)

The US Food and Drug Administration (FDA) has approved an injectable formulation of Bristol-Myers Squibb (New York Stock Exchange:Bmmi) Oncology drug Opdivo.

Previously, the PD-1 inhibitor drug was only available through intravenous infusion.

The injectable formulation, which will be branded Opdivo Qvantig, is approved for all previously approved products.